PHP
Parkman Healthcare Partners Portfolio holdings
AUM
$864M
1-Year Return
33.7%
This Quarter Return
+6.59%
1 Year Return
+33.7%
3 Year Return
+258.24%
5 Year Return
+878.92%
10 Year Return
–
AUM
$864M
AUM Growth
+$21.2M
(+2.5%)
Cap. Flow
+$19.1M
Cap. Flow
% of AUM
2.21%
Top 10 Holdings %
Top 10 Hldgs %
32.42%
Holding
103
New
11
Increased
47
Reduced
28
Closed
15
Top Buys
| 1 |
IQVIA
IQV
|
+$17.3M |
| 2 |
GeneDx Holdings
WGS
|
+$16.2M |
| 3 |
Danaher
DHR
|
+$9.25M |
| 4 |
DexCom
DXCM
|
+$8.34M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
+$7.63M |
Top Sells
| 1 |
Becton Dickinson
BDX
|
+$27.6M |
| 2 |
UnitedHealth
UNH
|
+$26.3M |
| 3 |
Stryker
SYK
|
+$10.8M |
| 4 |
Gilead Sciences
GILD
|
+$9.68M |
| 5 |
Tenet Healthcare
THC
|
+$7.84M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Arcellx
ACLX
$4.31B
| $11.5M | 1.32% |
174,276
+106,886
| +159% | +$7.04M |
|
27
QuidelOrtho
QDEL
$2.03B
| $11.1M | 1.28% |
386,646
+202,968
| +111% | +$5.85M |
|
28
Outset Medical
OM
$251M
| $10.5M | 1.21% |
549,052
+317,953
| +138% | +$6.11M |
|
|
MBX
29
MBX Biosciences, Inc. Common Stock
MBX
$334M
| $9.95M | 1.14% |
871,933
+543,610
| +166% | +$6.2M |
|
30
Xeris Biopharma Holdings
XERS
$1.24B
| $9.84M | 1.13% |
2,107,483
+327,029
| +18% | +$1.53M |
|
31
Nuvalent
NUVL
$5.93B
| $9.13M | 1.05% |
119,623
+9,635
| +9% | +$735K |
|
32
BioCryst Pharmaceuticals
BCRX
$1.69B
| $9.03M | 1.04% |
1,007,992
+7,430
| +0.7% | +$66.6K |
|
33
PTC Therapeutics
PTCT
$4.84B
| $8.87M | 1.02% |
181,643
-98,671
| -35% | -$4.82M |
|
34
Merus
MRUS
$5.28B
| $8.57M | 0.99% |
162,980
+134,750
| +477% | +$7.09M |
|
35
Edgewise Therapeutics
EWTX
$1.55B
| $8.49M | 0.98% |
647,331
+221,924
| +52% | +$2.91M |
|
36
ANI Pharmaceuticals
ANIP
$2.14B
| $8.38M | 0.96% |
128,478
+23,478
| +22% | +$1.53M |
|
37
Replimune Group
REPL
$469M
| $8.33M | 0.96% |
896,710
-53,689
| -6% | -$499K |
|
38
RxSight
RXST
$385M
| $8.24M | 0.95% |
633,874
+2,636
| +0.4% | +$34.3K |
|
39
Syndax Pharmaceuticals
SNDX
$1.41B
| $8.13M | 0.93% |
867,813
+272,826
| +46% | +$2.56M |
|
40
LivaNova
LIVN
$3.13B
| $7.88M | 0.91% |
175,000
+8,129
| +5% | +$366K |
|
|
UPB
41
Upstream Bio, Inc. Common Stock
UPB
$966M
| $7.86M | 0.9% |
715,504
+481,941
| +206% | +$5.29M |
|
42
KalVista Pharmaceuticals
KALV
$746M
| $7.68M | 0.88% |
679,063
-74,689
| -10% | -$844K |
|
43
Doximity
DOCS
$13.2B
| $7.41M | 0.85% |
120,834
+27,334
| +29% | +$1.68M |
|
44
Quest Diagnostics
DGX
$20.5B
| $7.36M | 0.85% |
40,997
-21,596
| -35% | -$3.88M |
|
45
Axogen
AXGN
$773M
| $7.32M | 0.84% |
674,551
+137,719
| +26% | +$1.49M |
|
46
Ascendis Pharma
ASND
$12B
| $7.27M | 0.84% |
+42,108
| New | +$7.27M |
|
47
Alphatec Holdings
ATEC
$2.31B
| $7.2M | 0.83% |
648,871
+202,765
| +45% | +$2.25M |
|
48
Castle Biosciences
CSTL
$660M
| $7.19M | 0.83% |
352,262
+1,711
| +0.5% | +$34.9K |
|
49
MannKind Corp
MNKD
$1.66B
| $7.11M | 0.82% |
1,900,918
-592,918
| -24% | -$2.22M |
|
50
OptimizeRx
OPRX
$350M
| $6.85M | 0.79% |
507,423
+32,423
| +7% | +$438K |
|